Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Entrada Therapeutics (TRDA) EBT: 2022-2025

Historic EBT for Entrada Therapeutics (TRDA) over the last 4 years, with Sep 2025 value amounting to -$43.5 million.

  • Entrada Therapeutics' EBT fell 173.60% to -$43.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$104.5 million, marking a year-over-year decrease of 236.64%. This contributed to the annual value of $66.5 million for FY2024, which is 449.59% up from last year.
  • Entrada Therapeutics' EBT amounted to -$43.5 million in Q3 2025, which was down 1.29% from -$42.9 million recorded in Q2 2025.
  • Entrada Therapeutics' EBT's 5-year high stood at $57.8 million during Q2 2024, with a 5-year trough of -$43.5 million in Q3 2025.
  • Its 3-year average for EBT is -$2.3 million, with a median of -$3.1 million in 2023.
  • The largest annual percentage gain for Entrada Therapeutics' EBT in the last 5 years was 910.98% (2024), contrasted with its biggest fall of 187.98% (2024).
  • Over the past 4 years, Entrada Therapeutics' EBT (Quarterly) stood at -$24.6 million in 2022, then surged by 137.52% to $9.2 million in 2023, then plummeted by 107.83% to -$724,000 in 2024, then tumbled by 173.60% to -$43.5 million in 2025.
  • Its EBT was -$43.5 million in Q3 2025, compared to -$42.9 million in Q2 2025 and -$17.3 million in Q1 2025.